How an industry actually grows: pharma in a small economy

Pharma looks like a science story. It's mostly a manufacturing, regulation and pricing story. A worked example of why sectors grow.

The question

"Country X's pharma industry is growing" is a headline, not an explanation. Why do some pharmaceutical sectors scale and others stall? Strip the headline and what actually drives the growth?

What's happening

Pharma is treated as a high-tech story — labs and discovery. In practice, in most emerging economies the growth that shows up in the numbers is lower down the chain: generic manufacturing and active pharmaceutical ingredients (APIs), not novel drug discovery.

How it actually works

An industry scales when four gears turn together. Miss one and growth stalls:

Gear What it is What blocks it
Manufacturing capability producing at scale, to spec, reliably capital, quality systems
Regulation approvals that unlock export markets audits, standards, certification
Cost base why production lands here labour, energy, logistics
Pricing access who buys it, and on what terms tenders, patents, trade rules

The mechanism is sequential:

  1. A country usually starts by making generics for its own market — the easiest rung, because the regulator is close and the buyer is domestic.
  2. Growth comes when regulatory approval abroad lets it export. Approval is the hinge: without a recognized certification, the manufacturing capacity has nowhere to sell.
  3. Real scale arrives when cost advantages (skilled labour, lower energy) let the country win contracts in other markets — this is where API production clusters form.
  4. The ceiling is set by pricing and patents. Off-patent molecules are a commodity race to the bottom; novel molecules are locked behind patent walls and huge R&D budgets.

That is why "pharma growth" is rarely about a discovery. It is a story about certification, cost curves and who gets to sell to whom.

The science is necessary. The growth is decided by manufacturing, regulation and price.

What's unknown

  • How much of the growth is durable versus a function of a single export market's demand.
  • Whether the sector can move up the chain from generic manufacturing to research, or whether that step requires a scale of capital small economies cannot raise.
  • Open: the certification bottleneck is the fascinating part and the one I understand least — how a local manufacturer actually earns the approval to export.

Reading

  • Pharmaceutical supply-chain and API-manufacturing analyses.
  • Trade/regulatory material on drug certification and export approval.